The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global CAR T-Cell Therapy for Multiple Myeloma Market Research Report 2025
Synopsis
CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for multiple myeloma.
The global CAR T-Cell Therapy for Multiple Myeloma market was valued at US$ 164 million in 2023 and is anticipated to reach US$ 999.8 million by 2030, witnessing a CAGR of 29.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for CAR T-Cell Therapy for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR T-Cell Therapy for Multiple Myeloma.
Report Scope
The CAR T-Cell Therapy for Multiple Myeloma market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CAR T-Cell Therapy for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR T-Cell Therapy for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Juno Therapeutics
Kite Pharma
Novartis
Collectis
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Multiple Myeloma
Refractory or Relapsed Multiple Myeloma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR T-Cell Therapy for Multiple Myeloma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
CARs are also known as chimeric immunoreceptors, chimeric T-cell receptors, artificial T-cell receptors or CAR T. they are used as an individual's own cells and re-engineers them to fight cancer. Though the market has witnessed several positive results of the clinical trial in the recent years, it is yet to receive an approval of the first CAR T-cell therapy for multiple myeloma.
The global CAR T-Cell Therapy for Multiple Myeloma market was valued at US$ 164 million in 2023 and is anticipated to reach US$ 999.8 million by 2030, witnessing a CAGR of 29.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for CAR T-Cell Therapy for Multiple Myeloma, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding CAR T-Cell Therapy for Multiple Myeloma.
Report Scope
The CAR T-Cell Therapy for Multiple Myeloma market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global CAR T-Cell Therapy for Multiple Myeloma market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the CAR T-Cell Therapy for Multiple Myeloma companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Juno Therapeutics
Kite Pharma
Novartis
Collectis
Segment by Type
Monotherapy
Combination Therapy
Segment by Application
Multiple Myeloma
Refractory or Relapsed Multiple Myeloma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of CAR T-Cell Therapy for Multiple Myeloma companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Monotherapy
1.2.3 Combination Therapy
1.3 Market by Application
1.3.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Multiple Myeloma
1.3.3 Refractory or Relapsed Multiple Myeloma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Perspective (2019-2030)
2.2 CAR T-Cell Therapy for Multiple Myeloma Growth Trends by Region
2.2.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 CAR T-Cell Therapy for Multiple Myeloma Historic Market Size by Region (2019-2024)
2.2.3 CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Region (2025-2030)
2.3 CAR T-Cell Therapy for Multiple Myeloma Market Dynamics
2.3.1 CAR T-Cell Therapy for Multiple Myeloma Industry Trends
2.3.2 CAR T-Cell Therapy for Multiple Myeloma Market Drivers
2.3.3 CAR T-Cell Therapy for Multiple Myeloma Market Challenges
2.3.4 CAR T-Cell Therapy for Multiple Myeloma Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top CAR T-Cell Therapy for Multiple Myeloma Players by Revenue
3.1.1 Global Top CAR T-Cell Therapy for Multiple Myeloma Players by Revenue (2019-2024)
3.1.2 Global CAR T-Cell Therapy for Multiple Myeloma Revenue Market Share by Players (2019-2024)
3.2 Global CAR T-Cell Therapy for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by CAR T-Cell Therapy for Multiple Myeloma Revenue
3.4 Global CAR T-Cell Therapy for Multiple Myeloma Market Concentration Ratio
3.4.1 Global CAR T-Cell Therapy for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by CAR T-Cell Therapy for Multiple Myeloma Revenue in 2023
3.5 CAR T-Cell Therapy for Multiple Myeloma Key Players Head office and Area Served
3.6 Key Players CAR T-Cell Therapy for Multiple Myeloma Product Solution and Service
3.7 Date of Enter into CAR T-Cell Therapy for Multiple Myeloma Market
3.8 Mergers & Acquisitions, Expansion Plans
4 CAR T-Cell Therapy for Multiple Myeloma Breakdown Data by Type
4.1 Global CAR T-Cell Therapy for Multiple Myeloma Historic Market Size by Type (2019-2024)
4.2 Global CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Type (2025-2030)
5 CAR T-Cell Therapy for Multiple Myeloma Breakdown Data by Application
5.1 Global CAR T-Cell Therapy for Multiple Myeloma Historic Market Size by Application (2019-2024)
5.2 Global CAR T-Cell Therapy for Multiple Myeloma Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America CAR T-Cell Therapy for Multiple Myeloma Market Size (2019-2030)
6.2 North America CAR T-Cell Therapy for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2019-2024)
6.4 North America CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size (2019-2030)
7.2 Europe CAR T-Cell Therapy for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2019-2024)
7.4 Europe CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Market Size (2019-2030)
8.2 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Market Size by Region (2019-2024)
8.4 Asia-Pacific CAR T-Cell Therapy for Multiple Myeloma Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America CAR T-Cell Therapy for Multiple Myeloma Market Size (2019-2030)
9.2 Latin America CAR T-Cell Therapy for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2019-2024)
9.4 Latin America CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Market Size (2019-2030)
10.2 Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2019-2024)
10.4 Middle East & Africa CAR T-Cell Therapy for Multiple Myeloma Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Juno Therapeutics
11.1.1 Juno Therapeutics Company Detail
11.1.2 Juno Therapeutics Business Overview
11.1.3 Juno Therapeutics CAR T-Cell Therapy for Multiple Myeloma Introduction
11.1.4 Juno Therapeutics Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2019-2024)
11.1.5 Juno Therapeutics Recent Development
11.2 Kite Pharma
11.2.1 Kite Pharma Company Detail
11.2.2 Kite Pharma Business Overview
11.2.3 Kite Pharma CAR T-Cell Therapy for Multiple Myeloma Introduction
11.2.4 Kite Pharma Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2019-2024)
11.2.5 Kite Pharma Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis CAR T-Cell Therapy for Multiple Myeloma Introduction
11.3.4 Novartis Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Collectis
11.4.1 Collectis Company Detail
11.4.2 Collectis Business Overview
11.4.3 Collectis CAR T-Cell Therapy for Multiple Myeloma Introduction
11.4.4 Collectis Revenue in CAR T-Cell Therapy for Multiple Myeloma Business (2019-2024)
11.4.5 Collectis Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
